How Much Longer Will We Put Up With $100,000 Cancer Drugs?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28187281.
- Also identified by DOI 10.1016/j.cell.2017.01.034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.
Medical subject headings
- Antineoplastic Agents
- Drug Costs
- Neoplasms